Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T19:00:24.194Z.
Calculation as of: 2026-10-06T19:00:24.194Z.
Quote observation: 2026-10-06T18:59:20.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 237c69f2886ce95022375c2c4ca3b4be9bdf1b13d47079a179ac8fcd7ebd926e
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Allarity Therapeutics, Inc.
Market Cap
$15.65M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$15.45M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$15.24M
Price/FCF Ratio
N/A
TTM Avg
82.38
3Y Avg
82.38
5Y Avg
82.38
Market Cap
$15.03M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$15.03M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$16.50M
Price/FCF Ratio
N/A
TTM Avg
43.53
3Y Avg
55.71
5Y Avg
97.87
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Allarity Therapeutics, Inc. (ALLR) | $15.65M | N/A | N/A | N/A | N/A |
| BioCardia, Inc. (BCDA)vs › | $15.93M | N/A | 121.92 | 75.43 | 64.77 |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $15.45M | N/A | N/A | N/A | N/A |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.24M | N/A | 82.38 | 82.38 | 82.38 |
| Pasithea Therapeutics Corp. (KTTA)vs › | $15.03M | N/A | N/A | N/A | N/A |
| Jin Medical International Ltd. (ZJYL)vs › | $15.03M | N/A | N/A | N/A | N/A |
| Dyadic International, Inc. (DYAI)vs › | $16.50M | N/A | 43.53 | 55.71 | 97.87 |
| TScan Therapeutics, Inc. (TCRX)vs › | $16.53M | N/A | N/A | N/A | N/A |
| Marker Therapeutics, Inc. (MRKR)vs › | $16.84M | N/A | N/A | N/A | N/A |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.24M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
